Efficacy and Safety of Tirzepatide in Japanese Participants With Obesity: A Subpopulation Analysis of the <scp>SURMOUNT</scp> ‐1 Trial

Authors

Yasushi Ishigaki (ORCID: https://orcid.org/0000-0003-2479-5752)
Tomotaka Shingaki (ORCID: https://orcid.org/0000-0003-1568-9763)
Tomonori Oura (ORCID: https://orcid.org/0000-0003-0872-8576)
Masamichi Yamada
Iichiro Shimomura

Institutions

Iwate Medical University (JP)
Eli Lilly (Japan) (JP)
Minamiaoyama Eye Clinic (JP)
The University of Osaka (JP)

Publication Details

Journal: Obesity
Published: 2026-01-30
DOI: https://doi.org/10.1002/oby.70131
Primary Topic: Bariatric Surgery and Outcomes
Type: article
Field-Weighted Citation Impact: 0.00

Funders

Eli Lilly and Company
AstraZeneca
Sanofi
Suzuken Memorial Foundation
Abbott Japan
Boehringer Ingelheim Japan
Novo Nordisk
Astellas Pharma
Astellas Foundation for Research on Metabolic Disorders
Manpei Suzuki Diabetes Foundation
Teijin Pharma
MSD K.K.
Eli Lilly Japan
Novo Nordisk Pharma
Daiichi Sankyo Europe

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Efficacy and Safety of Tirzepatide in Japanese Participants With Obesity: A Subpopulation Analysis of the SURMOUNT ‐1 Trial

Yasushi Ishigaki, Tomotaka Shingaki, Tomonori Oura, Masamichi Yamada et al.

Jan 30, 2026

Obesity

Bariatric Surgery and Outcomes

article

Efficacy and Safety of Tirzepatide in Japanese Participants With Obesity: A Subpopulation Analysis of the SURMOUNT ‐1 Trial

Yasushi Ishigaki, Tomotaka Shingaki, Tomonori Oura, Masamichi Yamada, Iichiro Shimomura

January 30, 2026article en

Abstract

No abstract available for this paper.

ObesityVol. 34(3)

Iwate Medical University (JP), Eli Lilly (Japan) (JP), Minamiaoyama Eye Clinic (JP), The University of Osaka (JP)

Eli Lilly and Company, AstraZeneca, Sanofi, Suzuken Memorial Foundation, Abbott Japan, Boehringer Ingelheim Japan, Novo Nordisk, Astellas Pharma, Astellas Foundation for Research on Metabolic Disorders, Manpei Suzuki Diabetes Foundation, Teijin Pharma, MSD K.K., Eli Lilly Japan, Novo Nordisk Pharma, Daiichi Sankyo Europe

Good health and well-being

Openalex Percentile: Top 72%

Bariatric Surgery and Outcomes

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.